Providence’s Post

🚀 Happy to share that my first article for GlobalData Healthcare was published last week, discussing #GLP-1 therapies and their potential in treating Metabolic-Associated Steatohepatitis (#MASH). In this piece, I explore how these therapies, traditionally used for diabetes and obesity, are now emerging as promising treatments for MASH—a condition with, up until recently, no approved therapies. This development marks a significant step forward in addressing a growing global health challenge. Looking forward to writing more of these in the future, covering the metabolic disease space! Check out the full article here to learn more: GLP-1 Therapies: A New Frontier in MASH Treatment

Rare diseases affect over 30 million individuals in the US. While innovative therapies offer hope, treating these conditions is complex. Pharmacy's pivotal role spans from diagnosis to ongoing support for patients, providers, and payers navigating treatment challenges. Collaborative efforts among stakeholders, including tailored care, value-based models, and outcome tracking, are crucial to ensuring access and optimizing outcomes for those with rare diseases. Read more here: https://lnkd.in/engGnfEM   #RareDiseaseDay #PharmacyTimesxMJH Pharmacy Times MJH Thought Leaders

#DidYouKnow that recent breakthroughs in cystic fibrosis (CF) treatment, like CFTR modulators, are extending life expectancy? With a projected 75% rise in the adult CF population by 2025, these advancements are reshaping the landscape of CF care. Stay informed about the latest developments in CF research! Download our report now- https://lnkd.in/gdcejdzF #cysticfibrosis #globalhealth #clinicaltrials

On #ClinicalTrialsDay, it is crucial to reflect on the challenges that clinical trials on rare diseases face and how we can overcome them to accelerate the development of new treatments. In this article, #Alcimed sheds light on how to improve knowledge of rare diseases and facilitate patient recruitment! #innovation #healthcare #clinicaltrials #rarediseases https://lnkd.in/dHW4VVa6

Join experts for insights on patient engagement, SDoH, and digital therapeutics in developing interventions for cardiometabolic diseases. Attend live on December 5th at 10 AM EST or access the webinar recording. #Type2Diabetes #ClinicalTrials #PatientCentered #CardiometabolicResearch #Obesity

Don’t miss out! Join experts and gain insights into the impact that patient engagement, SDoH, and digital therapeutics have on developing effective interventions for cardiometabolic diseases and conditions such as obesity, Type 2 diabetes, and ischemic heart disease. Register today to attend live on December 5th at 10 AM EST or to access the post-event webinar recording. #Type2Diabetes #ClinicalTrials #PatientCentered #CardiometabolicClinicalResearch #IschemicCardiovascularDisease #Obesity Christian Born Djurhuus Kevin Dolgin Mona Khalid Jonathan Goldman, MD MBA

Key opinion leaders (KOLs) interviewed by GlobalData highlight unmet needs in the kidney disease space, emphasizing the demand for next-generation therapies with alternate mechanisms of action. Ozempic, if approved, will be the first GLP-1 therapy option for patients with T2D and CKD. Learn more about how Ozempic can benefit CKD patients: #Healthcare #KidneyDisease #GlobalData #Ozempic #T2D #CKD

Integrated Genomic and Social Network Analyses of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in the Healthcare Setting https://lnkd.in/e2YZ4RE9

Integrated Genomic and Social Network Analyses of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in the Healthcare Setting https://lnkd.in/e2YZ4RE9

Integrated Genomic and Social Network Analyses of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in the Healthcare Setting https://lnkd.in/e2YZ4RE9